New hope for tough prostate cancer: immunotherapy meets targeted radiation

NCT ID NCT05682443

Ongoing Disease control Sponsor: OncoC4, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether adding an immunotherapy drug (ONC-392) to a targeted radiation therapy (Pluvicto) can help men with a hard-to-treat form of advanced prostate cancer. About 148 participants whose cancer has worsened despite standard treatments will receive either a low or high dose of ONC-392 plus Pluvicto. The goal is to see if the combination can shrink tumors or delay cancer growth, while monitoring for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ONC-392 (gotistobart) and lutetium Lu 177 vipivotide tetraxetan (Pluvicto)
What this could lead to: If successful, this combination could offer a new treatment option for men with advanced prostate cancer that has stopped responding to standard therapies, potentially slowing disease progression.
What could go wrong: This is an early-phase trial (Phase 1/2) with a small number of participants, so results may not apply broadly. The combination may cause significant side effects, including immune-related reactions and radiation toxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Contacts and locations

Locations

Chesapeake Urology Research Associates

Towson, Maryland, 21204, United States
Columbia University Irving Cancer Center

New York, New York, 10032, United States
Duke Cancer Center

Durham, North Carolina, 27710, United States
Emory University Winship Cancer Institute

Atlanta, Georgia, 30322, United States
Lahey Hospital & Medical Center

Burlington, Massachusetts, 01805, United States
Moffitt Cancer Cancer

Tampa, Florida, 33612, United States
NYU Langone Health, Laura & Isaac Perlmutter Cancer Center

New York, New York, 10016, United States
New Mexico Oncology Hematology Consultants

Albuquerque, New Mexico, 87109, United States
OHSU Knight Cancer Institute

Portland, Oregon, 97210, United States
Oncology and Hematology Associates Of Southwest Virginia USOR

Norton, Virginia, 24273, United States
Rocky Mountain Cancer Centers USOR

Aurora, Colorado, 80012, United States
Roswell Park Comprehensive Cancer Center

Buffalo, New York, 14203, United States
Rutgers Cancer Institute

New Brunswick, New Jersey, 08901, United States
The Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Baltimore, Maryland, 21202, United States
UC Davis Comprehensive Cancer Center

Sacramento, California, 95817, United States
UNC North Carolina Comprehensive Cancer Care Center

Chapel Hill, North Carolina, 27514, United States
UT Southwestern Medical Center

Dallas, Texas, 75390, United States
UW Carbone Cancer Center

Madison, Wisconsin, 53792, United States
University of Mississippi Medical Center

Jackson, Mississippi, 39216, United States
Virginia Cancer Specialists USOR

Fairfax, Virginia, 22031, United States
Virginia Oncology Associates USOR

Norfolk, Virginia, 23502, United States
XCancer/GU Research Network

Omaha, Nebraska, 68130, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.